Top Markets
#1 Cortex Cortex +32.97%
#2 DexNet DexNet +23.20%
#3 龙虾 (Lobster) 龙虾 (Lobster) +19.81%
#4 wojak wojak +17.68%
#5 Pons Pons +15.94%
#6 Akedo Akedo +13.13%
#7 MarsCoin MarsCoin +9.56%
#8 OpenEden OpenEden +9.38%
#9 EXOD EXOD +9.04%
#10 BNB Attestation Service BNB Attestation Service +8.85%
Coin of the day
Cortex Cortex
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Ambrx Biopharma Inc. Ambrx Biopharma Inc.

Ambrx Biopharma Inc.

AMAM
Classifica tra le azioni #6983
Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused... Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines. The firm utilizes its unique expanded genetic code technology platform to create these advanced therapies. Leading its pipeline is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is currently undergoing evaluation in several clinical investigations. These include pivotal Phase 2/3 trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer, alongside studies for other solid tumors. Additionally, Ambrx is progressing two earlier-stage drug candidates: ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for prostate cancer and other solid tumor indications; and ARX305, an anti-CD70 ADC, currently in investigational new drug (IND)-enabling studies for potential applications in renal cell carcinoma and other cancers. The company's portfolio also encompasses multiple immuno-oncology programs. Among these are ARX822, a fab-small molecule bispecific therapeutic in preclinical development for various cancers, and ARX102, an immuno-oncology IL-2 pathway agonist intended to stimulate the patient's immune system by targeting beta and gamma receptors on cytotoxic T cells. Founded in 2003 and headquartered in La Jolla, California, Ambrx Biopharma Inc. has established significant collaborations with various pharmaceutical partners, including Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health.
Prezzo delle azioni
$28.00
Ultima sincronizzazione: 2024-03-06
Capitalizzazione di mercato
$1.77B
Variazione (1 giorno)
0.07%
Variazione (1 anno)
0.00%
Paese
US
Scambia Ambrx Biopharma Inc. (AMAM)

Categoria

Healthcare
Utile per Ambrx Biopharma Inc. (AMAM)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Ambrx Biopharma Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Ambrx Biopharma Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH